title: Extracellular adenosine 5'-triphosphate (ATP) in the endolymphatic compartment influences cochlear function.
abstract: There is strong evidence for the presence of P2 purinoceptors on cochlear tissues, but the role of extracellular ATP in cochlear function is still unclear. Our previous studies have determined the presence of ATP in the cochlear fluids and indicated that the purinoceptors are substantially localized to the tissues lining the endolymphatic compartment. This implies that extracellular ATP may have an humoral role confined to the endolymphatic space. In order to study the influence of extracellular ATP in the endolymphatic space, a series of studies were undertaken in which ATP (10 microM to 10 mM) in artificial endolymph (EL) (test solution: 2-12.5 nl) was injected into the scala media and the effect on the cochlear microphonic (CM) and endocochlear potential (EP) evaluated. A double-barrelled pipette, with one barrel containing the test solution and the other artificial EL (control solution) was inserted into scala media of the third turn of the guinea-pig cochlea. A known volume (2-12.5 nl) of test or control solution was then pressure-injected into the space. ATP had a significant dose-dependent suppressive effect on both EP and CM with a threshold of approximately 2 x 10(-14) mol; the response was readily reversible, also in a dose-dependent fashion. Artificial EL of the same volume had no effect on EP and CM. The ATP effect on EP was blocked by the P2 purinoceptor antagonists suramin and reactive blue 2 (RB2). Neither adenosine (2 x 10(-13) to 2 x 10(-11) mol) nor suramin or RB2 on their own had any effect on EP and CM. This study provides the first evidence for an effect of extracellular ATP in the endolymphatic compartment on cochlear function which is mediated via P2 purinoceptors. This provides supporting evidence for an humoral role for extracellular ATP in the modulation of cochlear function.
authors.affiliation: Department of Physiology, University of Auckland, New Zealand.
authors.forename: D J
authors.initials: DJ
authors.lastname: Muñoz
authors.forename: P R
authors.initials: PR
authors.lastname: Thorne
authors.forename: G D
authors.initials: GD
authors.lastname: Housley
authors.forename: T E
authors.initials: TE
authors.lastname: Billett
authors.forename: J M
authors.initials: JM
authors.lastname: Battersby
mesh_terms: D000241:Adenosine / Q000494:pharmacology; D000255:Adenosine Triphosphate / Q000378:metabolism / Q000494:pharmacology* / Q000502:physiology; D000818:Animals; D003051:Cochlea / Q000187:drug effects* / Q000378:metabolism; D003055:Cochlear Microphonic Potentials / Q000187:drug effects; D004710:Endolymph / Q000187:drug effects* / Q000378:metabolism; D005260:Female; D006168:Guinea Pigs; D008297:Male; D010477:Perfusion; D010498:Perilymph / Q000187:drug effects / Q000378:metabolism; D011500:Protein Synthesis Inhibitors / Q000494:pharmacology*; D058919:Purinergic P2 Receptor Antagonists; D013498:Suramin / Q000494:pharmacology; D014227:Triazines / Q000494:pharmacology
chemical_list: D011500:Protein Synthesis Inhibitors; D058919:Purinergic P2 Receptor Antagonists; D014227:Triazines; C012842:Cibacron Blue F 3GA; D013498:Suramin; D000255:Adenosine Triphosphate; D000241:Adenosine